

Wednesday, May 2, 2007

8:30 - 10:00

Hall A

**S01 SYMPOSIUM:
PROTECTING THEIR FUTURE: THE ROLE OF THE PAEDIATRICIAN IN CERVICAL CANCER PREVENTION
SPONSORED BY SANOFI PASTEUR MSD**

Chairperson: **A. FINN, UK**

Time	Session Code		Abstract No
8:30	S1.1	Human Papillomavirus – From infection to Cancer M. STANLEY <i>Cambridge, UK</i>	7
8:50	S1.2	The epidemiology of HPV related diseases in Europe: Burden and potential for prevention X. CASTELLSAGUÉ <i>Barcelona, Spain</i>	8
9:10	S1.3	GARDASIL®: Proven efficacy against clinical disease N. MUÑOZ <i>Cali, Colombia</i>	9
9:30	S1.4	Human papillomavirus vaccine introduction: Lessons learnt from hepatitis B vaccination P. VAN DAMME <i>Antwerp, Belgium</i>	10
9:50		Closing remarks Questions and answers A. FINN <i>Bristol, UK</i>	
10:00		Coffee Break / Poster Viewing / Visit Exhibition	

Wednesday, May 2, 2007

10:30 - 12:00

Hall A

**S02 SYMPOSIUM:
CERVICAL CANCER VACCINATION: NEED FOR BROAD AND SUSTAINED PROTECTION
SPONSORED BY GLAXOSMITHKLINE**

Chairpersons: **P. VAN DAMME**, *Belgium*
H. BOGAERTS, *Belgium*

Time	Session Code		Abstract No
10:30	S2.1	HPV 16, 18 and beyond in cervical cancer and precursor lesions F.X. BOSCH <i>Barcelona, Spain</i>	11
10:50	S2.2	AS04 adjuvant system: Strong and sustained immune response to prevent cervical cancer F. ZEPP <i>Mainz, Germany</i>	12
11:10	S2.3	HPV 16/18 AS04-adjuvanted cervical cancer vaccine candidate: long-term safety and efficacy T.F. SCHWARZ <i>Wuerzburg, Germany</i>	13
11:30	S2.4	Cervical cancer prevention: One more reason for adolescent vaccination P. VAN DAMME <i>Antwerp, Belgium</i>	14
11:50		Questions and answers	
12:00		Lunch Break / Poster Viewing / Visit Exhibition	

Wednesday, May 2, 2007

13:00 - 14:30

Hall A

**S03 SYMPOSIUM:
NASOPHARYNGEAL COLONIZATION: THE FIRST STEP IN PNEUMOCOCCAL DISEASE - ASSESSING THE
IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE
SPONSORED BY WYETH**

Chairpersons: **G. CORDEIRO FERREIRA**, *Portugal*
B. FRITZELL, *France*

Time	Session Code		Abstract No
13:00		Welcome and Introduction	
13:05	S3.1	Carriage and natural immunity & vaccine induced immunity D. GOLDBLATT <i>London, UK</i>	15
13:25	S3.2	From carriage to disease: The impact of conjugate vaccine in vaccinated infants R. COHEN <i>Creteil, Val de Marne, France</i>	16
13:45	S3.3	The indirect effects of pneumococcal conjugate vaccine from colonization to disease: The who, what, when and how K.L. O'BRIEN <i>Baltimore, MD, USA</i>	17
14:05	S3.4	Do pneumococcal conjugate vaccines (PCVs) help in winning the battle against antibiotic-resistant S. pneumoniae (R-Pnc)? R. DAGAN <i>Beer-Sheva, Israel</i>	18
14:25		Questions and answers	
14:30		Coffee Break / Poster Viewing / Visit Exhibition	

Wednesday, May 2, 2007

15:00 - 16:30

Hall A

**S04 SYMPOSIUM:
MENINGOCOCCAL VACCINES: ACHIEVING BROAD PROTECTION ACCROSS EUROPE
THROUGH NOVEL VACCINES
SPONSORED BY NOVARTIS VACCINES**

Chairperson: **H. SCHMITT**, *Germany*

Time	Session Code		Abstract No
15:00	S4.1	Global epidemiology of meningococcal disease: The changing landscape of a well-recognised disease J.A. VÁZQUEZ <i>Madrid, Spain</i>	19
15:25	S4.2	Advances in conjugated meningococcal vaccines: Menjugate® to ACWY S. BLACK <i>Oakland, CA, USA</i>	20
15:50	S4.3	Meningococcal B vaccines: progress towards addressing an important unmet need D. GRANOFF <i>Oakland, CA, USA</i>	21
16:15		Panel discussion	
16:30		<i>Ice-cream break</i>	

Wednesday, May 2, 2007

16:50 - 18:20

Hall A

**S05 SYMPOSIUM:
RECENT DEVELOPMENTS IN VACCINATION AGAINST MENINGITIS AND ENCEPHALITIS
SPONSORED BY BAXTER**

Chairperson: **U. HEININGER**, *Switzerland*

Time	Session Code		Abstract No
16:50	S5.1	Tick borne encephalitis in children – the Austria success story W. ZENZ <i>Graz, Austria</i>	22
17:05	S5.2	Field effectiveness of vaccination against tick-borne encephalitis F.X. HEINZ , H. HOLZMANN, A. ESSL, M. KUNDI <i>Vienna, Austria</i>	23
17:20	S5.3	Meningococcal group C immunization – public health impact in Europe U. HEININGER <i>Basel, Switzerland</i>	24
17:35	S5.4	Meningococcal disease in the Netherlands in the era of conjugated menC vaccination S.C. DE GREEFF ¹ , L. SPANJAARD ² , A. VAN DER ENDE ² , L.M. SCHOULS ¹ , H.E. DE MELKER ¹ <i>¹Bilthoven, The Netherlands, ²Amsterdam, The Netherlands</i>	25
17:50	S5.5	Immunogenicity and booster response after infant vaccination with a reduced schedule of 7-valent pneumococcal conjugate and one of three monovalent meningococcal group C conjugate vaccines E. MILLER ¹ , J. SOUTHERN ¹ , N. ANDREWS ² , A. CROWLEY-LUKE ³ , M. HUDSON ³ , P. BALMER ⁴ , R. BORROW ⁴ <i>¹Colindale, London, UK, ²Colindale, London, UK, ³Salisbury, Wiltshire, UK, ⁴Manchester, UK</i>	26
18:05		Questions and answers	